Drug
Bepranemab
Bepranemab: highest development phase Phase 2, developed by UCB. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bepranemab NCT04867616 | Phase 2 | Alzheimer's Disease |
| bepranemab NCT04185415 | Phase 1 | Progressive Supranuclear Palsy |
Latest
No recent events.
Follow Bepranemab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.